
Quarterly ResultMay 12, 2026, 04:14 PM
SELLAS Q1 Net Loss $8.4M; REGAL Trial Nears 80-Event Milestone
AI Summary
SELLAS Life Sciences Group reported a net loss of $8.4 million for the first quarter ended March 31, 2026, compared to $5.8 million in Q1 2025. The company provided a corporate update, highlighting that its pivotal Phase 3 REGAL trial for Galinpepimut-S (GPS) in AML has reached 78 out of the 80 required events, signaling an imminent data readout. Additionally, SELLAS is actively dosing patients in its Phase 2 trial of SLS009 in newly diagnosed first-line AML, with topline data expected in Q4 2026. The company maintained a strong cash position of $107.1 million as of March 31, 2026, with an additional $7.5 million from warrant exercises in Q2.
Key Highlights
- Phase 3 REGAL trial for GPS in AML reached 78 events as of May 11, 2026, nearing the 80-event trigger for final analysis.
- Ongoing dosing of patients in Phase 2 trial of SLS009 in newly diagnosed first-line AML, with topline data expected in Q4 2026.
- Net loss for Q1 2026 was $8.4 million, compared to $5.8 million for Q1 2025.
- Research and development expenses increased to $5.1 million in Q1 2026 from $3.2 million in Q1 2025.
- General and administrative expenses rose to $4.1 million in Q1 2026 from $2.9 million in Q1 2025.
- Cash and cash equivalents totaled $107.1 million as of March 31, 2026.
- Received an additional $7.5 million in Q2 2026 from warrant exercises.
Price Impact
More from SLS